TRβ-Selective Triazine Agonists for Metabolic Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current thyroid hormone treatments for metabolic diseases like obesity, hyperlipidemia, and diabetes are limited by adverse side effects such as cardiovascular toxicity, necessitating the development of thyroid hormone analogs with increased TRβ selectivity and tissue-specific action.
Innovation Solution
Development of novel 2-phenyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile derivatives and similar compounds that act as thyroid hormone receptor agonists, providing therapeutic benefits without the undesirable effects of hyperthyroidism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If existing thyroid hormone receptor agonists are used to treat thyroid hormone deficiency, then thyroid hormone levels are improved, but cardiovascular side effects worsen
Solution Approach 1:
The patent segments the therapeutic effect from the harmful effects by developing selective agonists that target specific thyroid hormone receptor subtypes (TRα1, TRβ1, TRγ1) with different selectivity profiles. This allows selective activation of beneficial metabolic pathways while avoiding cardiovascular receptors, thereby separating the therapeutic benefit from the harmful cardiovascular side effects.
Solution Approach 2:
The invention applies local quality by designing compounds with specific molecular structures that confer selective affinity for particular receptor subtypes. The local chemical structure modifications enable the agonist to interact preferentially with certain receptor isoforms in specific tissues, achieving tissue-selective or receptor-subtype-selective action that preserves therapeutic effects while minimizing cardiovascular toxicity.
2Productivity
If non-selective thyroid hormone receptor agonists are used, then metabolic effects are improved, but selectivity and safety profile worsen
Solution Approach 1:
The patent employs parameter changes by systematically modifying molecular parameters such as substituent groups, stereochemistry, and structural motifs to tune the selectivity profile of the agonists. By changing these chemical parameters, the compounds achieve differential binding affinities for various thyroid hormone receptor subtypes, enabling selective metabolic activation without broad non-specific activity.
3Quantity of substance
If high doses of thyroid hormone are administered, then therapeutic effect is improved, but harmful side effects worsen
Solution Approach 1:
The invention extracts the harmful cardiovascular effects from the therapeutic metabolic effects by using selective receptor agonists. This extraction allows the therapeutic action to be achieved at lower, safer doses since the compound selectively activates only the desired receptor subtypes responsible for metabolic regulation, eliminating the need for high doses that would otherwise be required to achieve therapeutic effect but would cause cardiovascular toxicity.
Data Source
AI summary
A compound of formula (I) or (Ia), or a tautomer or a pharmaceutically acceptable salt thereof is provided. Compounds of formula (II) to (V), or a tautomer or a pharmaceutically acceptable salt thereof are also provided. These compounds and the pharmaceutical compositions containing them are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for other diseases such as NASH, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer and other disorders and diseases related thereto． (I), (Ia)